SCG101
Phase 1Biologic
SCG101 is one of 63 biologic programs targeting Hepatocellular Carcinoma. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
62
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
797 competitors in Hepatocellular Carcinoma
#DrugCompanyPhaseTrials
1Cysteine Hydrochloride
NovartisPreclinical
Viread
GileadPreclinical
Sovaldi
GileadPreclinical
Coreg
Akero TherapeuticsPreclinical
Miraclid
TTechpool Bio-Pharma Co., Ltd.
Preclinical
Vermox
WWim Janssens
Preclinical
Opdivo
Bristol-Myers SquibbPreclinical
Statin
Bristol-Myers SquibbPreclinical
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
PD-1 Inhibitors
BBioNTech US Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SCG101. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- SSCG Cell Therapy Pte. Ltd.